• Facebook
  • X
Phone: (843) 449-1010 | 823 82nd Parkway, Suite B, Myrtle Beach, SC 29572
Carolina Urologic Research Center - Myrtle Beach, SC
  • Home
  • About Us
  • Staff
    • Clinical Investigators
    • Clinical Staff
    • Associated Providers
  • Current Trials
    • Bladder Cancer
    • Prostate Cancer
    • Other
    • Patient Trials Form
  • Patient Info
    • Patient Info
    • Helpful Links
    • Q&A About Clinical Trials
  • Testimonials
  • In The News
    • In The News
  • Contact
  • Search
  • Menu Menu
Blog - Latest News
You are here: Home1 / Dr. Shore Conducts the Poster Presentation at the SUO 2015 Conference in Washington, DC “Significant Reduction in Therapeutic Burden from Use of CCP Test in Treatment Decisions among Newly Diagnosed Prostate Cancer Patients in a Large Prospective Registry” Please join us Wednesday, 12/2 • 4:30pm2 / 12.1-Prolaris

12.1-Prolaris

December 1, 2015/by CURC

Share this entry
  • Share on Facebook
  • Share on X
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail
/wp-content/uploads/logo-1.png 0 0 CURC /wp-content/uploads/logo-1.png CURC2015-12-01 09:08:342015-12-01 09:08:3412.1-Prolaris

Current Happenings

  • Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
  • START Further Expands Its Global Oncology Site Network with the Addition of Carolina Urologic Research Center
  • Final Version: Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy
  • The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer
  • Advances in Prostate Cancer Care: Genetic Testing, Teamwork, and ARPIs
  • Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer
  • Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
  • Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now

Archives

Contact

Carolina Urologic Research Center
823 82nd Parkway, Suite B
Myrtle Beach, SC 29572

Phone: (843) 839-1679
Fax: (843) 286-0119

Email:
info@curcmb.com

Directions

Recent Happenings

  • Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
  • START Further Expands Its Global Oncology Site Network with the Addition of Carolina Urologic Research Center
  • Final Version: Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy
  • The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer

Our Affiliates

©2025 Carolina Urologic Research Center, LLC | All Rights Reserved | Site Design by Studio303, Inc.
  • Facebook
  • X
Scroll to top